Atea notifies trade from stock option exercises
Primary insiders Juha Sihvonen and Steinar Sønsteby exercised and transferred options, resulting in share rights.
See the latest news and media coverage for Atea. We track all announcements, press releases, and industry mentions in real time, all in one place.
Leading provider of IT infrastructure solutions
atea.comLast updated
In short: Atea met Phase 3 endpoints for its hepatitis C drug regimen and reported Q2 2026 revenue growth of 12.5% to NOK 18.9 billion.
Primary insiders Juha Sihvonen and Steinar Sønsteby exercised and transferred options, resulting in share rights.
Gross sales rose 12.5% to NOK 18.9 billion, with EBIT up 19.2% and net profit at NOK 218 million.
The report moves from July 16 to July 15 at 17:30 CET to avoid World Cup semifinals.
Revenue will be recognized on a net basis, restating prior years' statements with no profit impact.
Sep. 01 SB1 Markets downgrades Atea to neutral (buy), target price NOK 180 (175) FW Jul. 17 Danske Bank upgrades Atea to buy (hold), price...
Atea ASA is a holding company based in Norway that provides a range of services to its subsidiaries. The company's subsidiaries are engaged...
HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.
Earnings call Atea delivered strong Q2 2026 results, with revenue up 12.5% YoY to NOK 18.9 billion and EBIT rising 19.2% to NOK 320 million...
Track Atea and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Atea and other trending companies.